Hospital - First-line enzalutamide, docetaxel combination improves disease control in advanced prostate cancer

SAN FRANCISCO - The addition of enzalutamide to docetaxel improved 6-month disease control and prolonged PFS as first-line therapy for men with metastatic castration-resistant...